This study investigates advanced colorectal cancer and pancreatic ductal adenocarcinoma. It involves patients with these conditions who have already undergone first-line chemotherapy.
The study evaluates the effects of a vaccine targeting KRAS mutations when combined with two other investigational medications. It focuses on understanding the immune response and the overall effectiveness of this combination treatment.
- Who can participate: Adults aged 18 and older with colorectal or pancreatic cancer that cannot be surgically removed can participate. They must have specific KRAS mutations and have previously received chemotherapy.
- Study details: Participants will receive a vaccine and two investigational medications. A placebo is not used in this study.
How understandable was the trial content above?
Hard to understand
Easy to understand